Boston Scientific Announces Decision to Acquire CryoVascular Systems
(April 18, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has exercised its option to acquire CryoVascular Systems, Inc., a privately held company located in Los Gatos, CA. Boston Scientific currently distributes CryoVascular's proprietary angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries. Terms of the acquisition were not disclosed.

CryoVascular Systems has developed a proprietary technology known as the PolarCath™ Peripheral Dilatation System, which utilizes liquid nitrous oxide to provide precise cooling of the diseased artery during balloon angioplasty. This procedure is known as CryoPlasty™. The PolarCath system is designed to revascularize the artery and reduce the post-procedure rate of restenosis. Restenosis often requires patients to have a repeat angioplasty procedure or surgery. The repeat procedure rate for patients treated with current balloon angioplasty and stent technology of the femoral-popliteal arteries is reported to be as high as 30-40 percent.

"Boston Scientific is continually searching for innovative technologies to treat peripheral vascular disease," said Paul LaViolette, Boston Scientific Chief Operating Officer. "The CryoPlasty procedure has become an important option for physicians whose patients are suffering from this disease. We have been impressed by the strong reception of the CryoPlasty procedure among physicians and look forward to continuing to offer this treatment option as part of our peripheral portfolio.